Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review

Table 14 Individual studies included for mucosal healing in ulcerative colitis

Study	Country	Intervention	Comparator	Study design	Follow-up	N	Mucosal healing
Prieux-Klotz et al[37]	France	AZA or 6-MP	-	Retrospective cohort	38 mo	80	43.7%1
Yamamoto et al[38]	Japan	Tacrolimus	Anti-TNF	Retrospective	12 wk	73	32% (tacrolimus); 28% (anti-TNF); P = 0.862
Ogata et al[39]	Japan	Tacrolimus	Placebo	RCT	2 wk	62	43.8% (tacrolimus); 13.3% (placebo); P = 0.0123
		Tacrolimus	Placebo	RCT	12 wk	21	85.7% (tacrolimus)3
Oshitani et al[47]	Japan	Prednisolone	Methylprednisolone	Retrospective cohort	6 wk	71	78% (prednisolone); 82% (methylprednisolone)4

¹Endoscopic mucosal healing was defined by endoscopic Mayo score of 0 or 1 and ulcerative colitis endoscopic index of severity ≤ 2;

²Endoscopic healing was defined as an endoscopic score of 0 or 1;

³Mucosal healing was defined as mucosal appearance subscore of 0 or 1;

⁴Endoscopic change considers endoscopic remission (no ulcers, no erosion, no friability) and endoscopic improvement (ulcers, erosion and friability decreased compared with previous findings). 6-MP: 6-mercaptopurine; AZA: Azathioprine; n: Number of patients; RCT: Randomized clinical trial; TNF: Tumor necrosis factor.